The previous WHO classification divided pituitary tumors into categories such as Btypical^adenomas, Batypical^adeno-mas, and pituitary carcinomas based on histopathologic features [1] . This seems to be the basis of classification used by Ceccato et al., understandably, given that their mean followup time was approximately 5 years. However, these classifications do not always correlate with the clinical behaviors of the tumors, and there is variation in how these tumors present in patients. The latest WHO classification system utilizes modern genetic and molecular characteristics in its classification scheme. Using the modern WHO classification system, more accurate tumor subtyping, assessment of the tumor proliferation profile by mitotic count and Ki-67 index, and using clinical parameters such as tumor invasion (characterized by MRI or operative assessment) allow for more individualized characterization [2] .
There is some difficulty in classifying pituitary tumors as Ceccato et al. have done. Indeed, such a means of determining tumor aggressiveness is best done post hoc, after one has surgically ascertained the level of invasiveness and can evaluate the tumor histopathologically. This may lead to avoiding a more extensive operation to treat an aggressive tumor. The level of tumor invasiveness is not always ascertainable with even a high-quality MRI, as even very large or invasivelooking tumors may have a well-delineated capsule, not truly invading adjacent structures, and be fully resectable [3] . Although helpful in guiding post-surgical treatment and prompting early adjuvant treatment, the system developed by Ceccato et al. does not always allow for planning an aggressive operation to deal with an aggressive tumor. A means of evaluating pituitary tumors that allows for proper surgical planning to appropriately treat aggressive tumors aggressively is key.
Given the rise of machine learning and the ability of computers to analyze massive amounts of data and the radiologic patterns of thousands of MRI scans on patients with brain tumors, and to correlate them with their treatments and outcomes [4] , it is not difficult to imagine a Bbig-data^solution to identifying potentially aggressive pituitary adenomas. The work presented by Ceccato et al. is an important step in this direction and represents a laudable effort to systematically approach aggressive pituitary tumors to ensure proper treatment. It will be important to use the full armament of novel genetic testing and radiologic workup to understand these tumors and their response to both surgical and adjuvant treatments. Additionally, these factors can be used to guide treatment based on these characteristics, allowing for more individualized targeted treatment strategies-something that is imperative in these patients whose aggressive tumors inherently require aggressive treatments.
